![Western Blot: IL1RL1 Antibody [NBP2-53096] - Rat tissue extract (50 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with ST2 antibody [N1C1] diluted at 1:500.](http://images.novusbio.com/fullsize/IL1RL1-Antibody-Western-Blot-NBP2-53096-img0003.jpg "Western Blot: IL1RL1 Antibody [NBP2-53096] - Rat tissue extract (50 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with ST2 antibody [N1C1] diluted at 1:500.")
| Reactivity | Mu, Rt, HuSpecies Glossary |
| Applications | WB, IHC |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Immunogen | Recombinant protein encompassing a sequence within the center region of human ST2/IL-33R. The exact sequence is proprietary. |
| Localization | Isoform C: Cell membrane , Isoform B: Secreted , Cell membrane; Single-pass type I membrane protein |
| Predicted Species | Human (100%). Backed by our 100% Guarantee. |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | IL1RL1 |
| Purity | Antigen Affinity-purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
|
| Theoretical MW | 63 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
|
| Publications |
|
| Storage | Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles. |
| Buffer | 0.1M Tris (pH 7), 0.1M Glycine, 10% Glycerol |
| Preservative | 0.01% Thimerosal |
| Purity | Antigen Affinity-purified |
![Western Blot IL-33 Antibody [Unconjugated]](https://images.novusbio.com/images2/IL-33_AF3626_Western_Blot_11104.jpg)
![Neutralization IL-33 Antibody [Unconjugated]](https://images.novusbio.com/images2/IL33_AF3626_Block_Neutralize_16781.jpg)
![Immunohistochemistry IL-33 Antibody [Unconjugated]](https://images.novusbio.com/images2/IL33_AF3626_ELISA_Capture_17376.jpg)
![Simple Western Albumin Antibody (188835) [Unconjugated] - Serum](https://images.novusbio.com/images2/Albumin_MAB1455_Simple_Western_21888.jpg)
![Immunocytochemistry Albumin Antibody (188835) [Unconjugated] - Serum](https://images.novusbio.com/images2/Albumin_MAB1455_Immunocytochemistry__Immunofluorescence_17777.jpg)
![Immunohistochemistry Albumin Antibody (188835) [Unconjugated] - Serum](https://images.novusbio.com/images2/Albumin_MAB1455_Immunohistochemistry_23317.jpg)
Secondary Antibodies |
Isotype Controls |
Research Areas for ST2/IL-33R Antibody (NBP2-53096)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
| Gene Symbol | IL1RL1 |
![Western Blot: IL1RL1 Antibody [NBP2-53096] - Whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with ST2 antibody [N1C1] diluted at 1:500.](http://images.novusbio.com/fullsize/IL1RL1-Antibody-Western-Blot-NBP2-53096-img0002.jpg "Western Blot: IL1RL1 Antibody [NBP2-53096] - Whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with ST2 antibody [N1C1] diluted at 1:500.")
![Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-31020241611354.jpg "Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-310202416114743.jpg "Western Blot: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: ST2/IL-33R Antibody [NBP2-53096] - p38 beta mediates the IL-33-induced IA decrease. A, immunoblot analysis of p38 alpha & p38 beta protein abundance in DRGs. Mouse brains were used as positive controls. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. B, time course of IA changes (left) & bar graph (right) indicating the effect of 50 ng/mL IL-33 on IA in the presence of JX-401 (50 nM, n = 8 cells). The application of 50 nM JX-401 (n = 6 cells) alone had no significant effect on IA. Arabic numerals indicate the points utilized for the example current traces. C, immunoblot analysis showing that the protein expression level of p38 beta was significantly reduced in the p38 beta -siRNA-treated groups, while the expression of p38 alpha was not affected. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. D, example traces (left) & bar graph (right) demonstrating the effects of 50 ng/mL IL-33 on IA in cells treated with control siRNA (NC-siRNA, n = 9 cells) or p38 beta -siRNA (n = 11 cells). **p < 0.01 vs. control + NC-siRNA group, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-310202416121979.jpg "Western Blot: ST2/IL-33R Antibody [NBP2-53096] - p38 beta mediates the IL-33-induced IA decrease. A, immunoblot analysis of p38 alpha & p38 beta protein abundance in DRGs. Mouse brains were used as positive controls. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. B, time course of IA changes (left) & bar graph (right) indicating the effect of 50 ng/mL IL-33 on IA in the presence of JX-401 (50 nM, n = 8 cells). The application of 50 nM JX-401 (n = 6 cells) alone had no significant effect on IA. Arabic numerals indicate the points utilized for the example current traces. C, immunoblot analysis showing that the protein expression level of p38 beta was significantly reduced in the p38 beta -siRNA-treated groups, while the expression of p38 alpha was not affected. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. D, example traces (left) & bar graph (right) demonstrating the effects of 50 ng/mL IL-33 on IA in cells treated with control siRNA (NC-siRNA, n = 9 cells) or p38 beta -siRNA (n = 11 cells). **p < 0.01 vs. control + NC-siRNA group, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-31020241613611.jpg "Western Blot: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] - The IL-33-induced IA decrease requires Syk. A, effects of 50 ng/mL IL-33 on protein abundance of phospho-JAK2 (p-JAK2)/total JAK2 (t-JAK2). Blots are representative of three independent experiments w/ beta -tubulin serving as a loading control. B, colabeling (white arrows) of ST2 & JAK2 & Syk in mouse DRG sections. Scale bar, 50 µm. C, time course of IA changes (left) & bar graph (right) showing that pretreatment of DRG neurons w/ AG490 (10 µM) did not affect IL-33-induced IA response (n = 8 cells). Application of 10 µM AG490 alone did not affect IA (n = 7 cells). Arabic numerals indicate points utilized for example current traces. D, effects of 50 ng/mL IL-33 on p-Syk protein abundance in presence/absence of ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) in DRG cells. Blots are representative of three independent experiments w/ beta -tubulin serving as a loading control. **p < 0.01 vs. control, unpaired t test. E-G, time course of IA changes showing that pretreating DRG neurons w/ R406/GS9973, but not KT-5720, prevented IL-33-induced IA response. Arabic numerals indicate points utilized for example current traces. H, bar graph showing effect of 50 ng/mL IL-33 on IA in cells pretreated w/ R406 (1 µM, n = 11 cells), GS9973 (10 µM, n = 8 cells), & KT-5720 (1 µM, n = 9 cells). Application of 1 µM R406 (n = 7 cells), 10 µM GS9973 (n = 6 cells)/1 µM KT-5720 (n = 7 cells) alone had no significant effect on IA. **p < 0.01 vs. control, paired t test. I, colabeling (white arrows) of ST2 & PKA in mouse DRG sections. Scale bar, 50 µm. J, bar graph demonstrating effect of 20 µM forskolin on IA in presence (n = 7 cells)/absence (n = 5 cells) of KT-5720 (1 µM). ***p < 0.001 vs. forskolin w/out KT-5720, paired t test. Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-310202416114719.jpg "Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] - The IL-33-induced IA decrease requires Syk. A, effects of 50 ng/mL IL-33 on protein abundance of phospho-JAK2 (p-JAK2)/total JAK2 (t-JAK2). Blots are representative of three independent experiments w/ beta -tubulin serving as a loading control. B, colabeling (white arrows) of ST2 & JAK2 & Syk in mouse DRG sections. Scale bar, 50 µm. C, time course of IA changes (left) & bar graph (right) showing that pretreatment of DRG neurons w/ AG490 (10 µM) did not affect IL-33-induced IA response (n = 8 cells). Application of 10 µM AG490 alone did not affect IA (n = 7 cells). Arabic numerals indicate points utilized for example current traces. D, effects of 50 ng/mL IL-33 on p-Syk protein abundance in presence/absence of ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) in DRG cells. Blots are representative of three independent experiments w/ beta -tubulin serving as a loading control. **p < 0.01 vs. control, unpaired t test. E-G, time course of IA changes showing that pretreating DRG neurons w/ R406/GS9973, but not KT-5720, prevented IL-33-induced IA response. Arabic numerals indicate points utilized for example current traces. H, bar graph showing effect of 50 ng/mL IL-33 on IA in cells pretreated w/ R406 (1 µM, n = 11 cells), GS9973 (10 µM, n = 8 cells), & KT-5720 (1 µM, n = 9 cells). Application of 1 µM R406 (n = 7 cells), 10 µM GS9973 (n = 6 cells)/1 µM KT-5720 (n = 7 cells) alone had no significant effect on IA. **p < 0.01 vs. control, paired t test. I, colabeling (white arrows) of ST2 & PKA in mouse DRG sections. Scale bar, 50 µm. J, bar graph demonstrating effect of 20 µM forskolin on IA in presence (n = 7 cells)/absence (n = 5 cells) of KT-5720 (1 µM). ***p < 0.001 vs. forskolin w/out KT-5720, paired t test. Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Bioactivity IL-4 [Unconjugated]](https://images.novusbio.com/images/protein/6507-ilcf_recombinant-human-il-4-cho-expressed-protein-cf-bioactivity-272020133214.jpg)
![SDS-PAGE TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNF-alpha_210-TA_256.jpg)
![Bioactivity TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNFalpha_210TA_1658.jpg)
![SEC-MALS TNF-alpha [Unconjugated]](https://images.novusbio.com/images/210-ta_recombinant-human-tnf-alpha-protein-sec-mals-35202312244..jpg)
![SDS-PAGE IL-1 beta/IL-1F2 [Unconjugated]](https://images.novusbio.com/images2/IL-1_beta_201-LB_304.jpg)
![Bioactivity IL-1 beta/IL-1F2 [Unconjugated]](https://images.novusbio.com/images2/IL-1_beta_201-LB_306.jpg)
![SEC-MALS IL-1 beta/IL-1F2 [Unconjugated]](https://images.novusbio.com/images/201-lb_recombinant-human-il-1-beta-il-1f2-protein-sec-mals-123202491556.jpg)
![N/A IL-5 [HRP]](https://images.novusbio.com/images2/IL-5_M5000_ELISA_237.jpg)
![N/A IL-5 [HRP]](https://images.novusbio.com/images2/DATA_IL5_M5000_ELISA_935.jpg)
![N/A IL-13 [Biotin]](https://images.novusbio.com/images2/DATA_IL13_DY413_ELISA_2010.jpg)
![Immunocytochemistry Insulin Antibody (182410) [Unconjugated]](https://images.novusbio.com/images2/Insulin_MAB1417_Immunocytochemistry_9376.jpg)
![Immunohistochemistry Insulin Antibody (182410) [Unconjugated]](https://images.novusbio.com/images2/mab1417_human-bovine-mouse-insulin-mab-clone-182410-immunohistochemistry-308202115145.jpg)
![N/A IL-10 [Biotin]](https://images.novusbio.com/images2/DATA_IL10_DY417_ELISA_2014.jpg)
![Bioactivity IL-2 [Unconjugated]](https://images.novusbio.com/images/202-il_recombinant-human-il-2-protein-bioactivity-174202314946.jpg)
![Flow Cytometry IL-1 RAcP/IL-1 R3 Antibody [Unconjugated]](https://images.novusbio.com/images/antibody/af676_human-il-1-racp-il-1-r3-affinity-purified-polyclonal-ab-flow-cytometry-1520247473.jpg)
![Bioactivity IFN-gamma [Unconjugated]](https://images.novusbio.com/images2/IFNgamma_285IF_2848.jpg)
![SDS-PAGE IFN-gamma [Unconjugated]](https://images.novusbio.com/images2/IFN-gamma_285-IF_230.jpg)
![SEC-MALS IFN-gamma [Unconjugated]](https://images.novusbio.com/images/285-if_recombinant-human-ifn-gamma-protein-sec-mals-1520239228..jpg)
![SDS-PAGE TRANCE/TNFSF11/RANK L [Unconjugated]](https://images.novusbio.com/images2/TRANCE_462-TR_634.jpg)
![Bioactivity TRANCE/TNFSF11/RANK L [Unconjugated]](https://images.novusbio.com/images2/TRANCE_462-TR_645.jpg)
![IL-18/IL-1F4 [HRP]](/sites/all/modules/enterprise-tech/et_datasheets/images/novus_guarantee.png "IL-18/IL-1F4 [HRP]")
![Bioactivity GM-CSF [Unconjugated]](https://images.novusbio.com/images/protein/7954-gmcf_recombinant-human-gm-csf-cho-expressed-protein-cf-bioactivity-272020121514.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")